Concord Asset Management LLC VA Has $1.12 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Concord Asset Management LLC VA increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 16.7% during the third quarter, HoldingsChannel.com reports. The fund owned 1,064 shares of the biopharmaceutical company’s stock after purchasing an additional 152 shares during the period. Concord Asset Management LLC VA’s holdings in Regeneron Pharmaceuticals were worth $1,119,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in REGN. Quent Capital LLC increased its holdings in shares of Regeneron Pharmaceuticals by 5.1% during the 1st quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock valued at $375,000 after acquiring an additional 19 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 37.2% during the 1st quarter. Acadian Asset Management LLC now owns 62,141 shares of the biopharmaceutical company’s stock valued at $59,794,000 after acquiring an additional 16,856 shares during the last quarter. Jacobi Capital Management LLC grew its holdings in Regeneron Pharmaceuticals by 1.8% in the 1st quarter. Jacobi Capital Management LLC now owns 1,139 shares of the biopharmaceutical company’s stock valued at $1,096,000 after buying an additional 20 shares during the last quarter. Covestor Ltd grew its holdings in Regeneron Pharmaceuticals by 7.4% in the 1st quarter. Covestor Ltd now owns 202 shares of the biopharmaceutical company’s stock valued at $195,000 after buying an additional 14 shares during the last quarter. Finally, O Shaughnessy Asset Management LLC grew its holdings in Regeneron Pharmaceuticals by 17.5% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 6,920 shares of the biopharmaceutical company’s stock valued at $6,660,000 after buying an additional 1,030 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $756.81 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company has a market capitalization of $83.17 billion, a PE ratio of 18.73, a price-to-earnings-growth ratio of 2.86 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a one year low of $753.69 and a one year high of $1,211.20. The business has a 50 day simple moving average of $985.21 and a 200 day simple moving average of $1,033.97.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 7.48% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have issued reports on REGN shares. Leerink Partnrs lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Morgan Stanley lowered their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Wells Fargo & Company lowered their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a report on Tuesday, October 22nd. Piper Sandler lowered their target price on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Finally, Barclays lowered their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,099.55.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.